A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms OASIS-1
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2017 Results reporting the efficacy results by clinical infection type and pathogen presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 25 Apr 2017 Results trial data for treatment effects on lesion size and specific local clinical signs of ABSSSI presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 25 Apr 2017 Results reporting efficacy outcomes by geographic region presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top